July 2013 | Oncology & Biotech News

Consolidation of Oncology Care Continues

August 21, 2013

An approximately 20% increase was seen in both community oncology clinics closing and merging with hospitals, demonstrating a continuing trend toward the consolidation of cancer care delivery.

Subgroup Analysis: Certain Patients May Benefit More From Eribulin

August 19, 2013

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

Experts Discuss Manipulation of T Cells for Therapy in Hematologic Malignancies

August 16, 2013

Finding new ways of manipulating the body's own defenses to better combat various hematologic malignancies is yielding some interesting results and could represent a very promising new field of care for patients dealing with these disorders.

ASCO 2013: Humanity Meets Immunity

August 13, 2013

While the anti-T-cell-checkpoint approach is far from perfect, the demonstrated ability for humanity to overcome evolutionary design and break tumor cell tolerance to turn the tide against cancer is nothing less than inspiring.

Cabozantinib Benefit Greater in MTC Patients With RET and RAS Mutations

August 01, 2013

A detailed analysis of previously reported data on the multikinase inhibitor cabozantinib in medullary thyroid cancer found that patients with mutations of RET and RAS experienced a significantly higher benefit than patients without those mutations.

T-VEC Delivers Durable Responses in Unresectable Melanoma

July 31, 2013

T-VEC manifested significant gains in durable response rate and other key clinical indicators in patients with advanced melanoma in what researchers described as the first phase III trial demonstrating the efficacy of an oncolytic virus immunotherapy.

Predicting Treatment Outcomes in Older Adults With AML

July 31, 2013

Measurable patient characteristics that predict better tolerance have not been widely studied and are desperately needed in clinical practice to inform treatment decision-making and individualize care for each older adult with AML.

Studies Highlight Newly Approved and Novel Multiple Myeloma Treatments

July 26, 2013

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide, as well as research involving the novel agents daratumumab and elotuzumab.